E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Diabetes Type 2 with existing cardiovascular disease |
Diabetes Typ 2 mit bestehender kardiovaskulärer Erkrankung |
|
E.1.1.1 | Medical condition in easily understood language |
Diabetes Type 2 with existing cardiovascular disease |
Diabetes Typ 2 mit bestehender Herz-Kreislauf-Erkrankung |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Effect of Liraglutide treatment for 3 months vs. placebo on metabolic profile of patients with type 2 diabetes and existing cardiovascular disease. |
|
E.2.2 | Secondary objectives of the trial |
Effect of Liraglutide treatment for 3 months vs. placebo on left ventricular systolic and diastolic function by echocardiography, energy expenditure and respiratory exchange ratio, the incidence of supraventricular and ventricular arrhythmias (24h holter ECG), systemic low grade inflammation as assessed by cytokine profile and circulating leukocyte populations and microbiome composition in patients with type 2 diabetes and existing cardiovascular disease. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Type 2 diabetes 2. Serum levels of HbA1c ≥ 7,0% 3. Age ≥ 18 years 4. Patients with existing cardiovascular disease: coronary heart disease, cerebrovascular disease, peripheral vascular disease or chronic kidney disease of stage III or greater or chronic heart failure of NYHA II or III 5. Written informed consent prior to study participation |
|
E.4 | Principal exclusion criteria |
1. Type 1 diabetes 2. Treatment with GLP-1 receptor agonists or DPP-4 inhibitors within in the last 4 weeks 3. Patients with familiar or personal history of multiple endocrine neoplasia-type 2 or medullary C-cell cancer 4. Renal impairment (eGFR < 30 mL/min) 5. Occurrence of acute vascular events within 6 weeks before screening and randomization 6. Known or suspected hypersensitivity to Liraglutide 7. Pregnant females as determined by positive [serum or urine] hCG test at Screening or prior to dosing. Participants of child-bearing age should use adequate contraception as defined in the study protocol. 8. Lactating females 9. The subject has a history of any other illness, which, in the opinion of the Investigator, might pose an unacceptable risk by administering study medication. 10. The subject received an investigational drug within 30 days prior to inclusion into this study. 11. The subject has any current or past medical condition and/or required medication to treat a condition that could affect the evaluation of the study. 12. The subject is unwilling or unable to follow the procedures outlined in the protocol. 13. The subject is mentally or legally incapacitated. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Effect of Liraglutide 1.8 mg/d in comparison to placebo after 3 month on the metabolic profile using the discovery HD4 platform, which consists of 4 different methods: 2 separate reverse phase (RP)/UPLC-MS/MS with positive ion mode electrospray ionization (ESI), (RP)/UPLC-MS/MS with negative ESI, and (HILIC)/UPLC-MS/MS with negative ESI. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Effect of Liraglutide in comparison to placebo after 3 months on: - change in left ventricular diastolic function between baseline and after 12 weeks as determined by 2D and 3D parameter global Strain Rate E by echocardiography - change in left ventricular diastolic function between baseline and after 12 weeks as determined by standardized parameter E/é and left atrial (LA) volume by echocardiography - change in left ventricular systolic function by ejection fraction (EF) by echocardiography - blood pressure - body weight - NT-proBNP - lipid profile - serum levels of glucose, HbA1c, glucagon, insulin, C-Peptide, β-Hydroxybutyrate - Heart rate variability (24 h ECG) - Resting energy expenditure (measured by indirect calorimetry [CardioCoach CO2]) - Respiratory Exchange Ratio (measured by indirect calorimetry [CardioCoach CO2]) - Microbiome analysis by 16S metagenomics sequencing - Albumin excretion by 24 h urine collection - changes in inflammosome analyses assessed by cytokine array - changes in lipidomics analyses, parameters included in the metabolomic profile - changes in circulation inflammatory cell composition (flow cytometry analyses, FACS) - serum and urine samples in addition to blood mononuclear cell pellets are stored for further analyses |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 24 |
E.8.9.1 | In the Member State concerned days | |